Doing now what patients need next!
Read our community guidelines: https://go.roche.com/CG
Read our community guidelines: https://go.roche.com/CG
Location: Switzerland
Employees: 10001+
Total raised: $5.06B
Founded date: 1896
Investors 4
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Sofinnova ... | sofinnova.... |
| - | Lightstone... | lightstone... |
| - | Easton Cap... | eastoncapi... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.08.2021 | - | $5B | - |
| 15.10.2012 | Series D | $24.5M | - |
| 08.03.2012 | Series D | $21.5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 04.11.2021 | Roche Holding AG announces an Equity Buyback for 53,300,000 shares, for CHF 19,000 million. | Roche Holding AG (SWX:ROG) announces a share repurchase program. Under the program, the company will repurchase up to 53,300,000 shares for CHF 19,000 million. The shares will be repurchased at a price of CHF 356.93 per share. These shares ... |
| 15.11.2019 | Roche to Acquire Promedior | Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG;OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior’s entire portfolio of mole... |
| 15.11.2019 | Roche to Acquire Promedior | Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG;OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior’s entire portfolio of mole... |
| 15.10.2012 | Biotech startup can expand scope of lead fibrotic disease treatment thanks to new funding | The company is also accelerating the development of its drug candidate for fibrovascular retinal diseases such as age-related macular degeneration — a diseases that leads to blindness. It currently affects an estimated 1.75 million people i... |
| 15.10.2012 | Promedior Expands Series D Round to $24.5M | MALVERN, PA, Clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that it has completed a $24.5 million Series D financing round. >> Click here for more funding ... |
| 15.10.2012 | Promedior Adds $3M in Series D Financing | Promedior, Inc., a Malvern, PA-based clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, has adding $3m in a second closing of its $24.5m Series D financing. The provider of the funding... |
| 13.03.2012 | Promedior Secures $21.5M Series D | MALVERN, PA, Clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, recently announced that it has raised $21.5M in a first closing of a Series D financing round. >... |
| 08.03.2012 | Promedior Raises $21.5M in Series D Financing | Promedior, Inc., a Malvern, PA-based clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, has raised $21.5m in a first closing of a Series D financing. The round was l... |
| 08.03.2012 | Fibrotic disease company raises $21 million in series D round | The financing was led by Fibrotic Ventures. It also received additional funding from existing venture investors such as Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Invest... |
Show more